These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 1416573)

  • 1. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion.
    Lim MJ; Barkan AL; Buda AJ
    Ann Intern Med; 1992 Nov; 117(9):719-26. PubMed ID: 1416573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide.
    Colao A; Marzullo P; Cuocolo A; Spinelli L; Pivonello R; Bonaduce D; Salvatore M; Lombardi G
    Clin Endocrinol (Oxf); 2003 Feb; 58(2):169-76. PubMed ID: 12580932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide treatment of acromegaly. A randomized, multicenter study.
    Ezzat S; Snyder PJ; Young WF; Boyajy LD; Newman C; Klibanski A; Molitch ME; Boyd AE; Sheeler L; Cook DM
    Ann Intern Med; 1992 Nov; 117(9):711-8. PubMed ID: 1416572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular effects of the somatostatin analog octreotide in acromegaly.
    Chanson P; Timsit J; Masquet C; Warnet A; Guillausseau PJ; Birman P; Harris AG; Lubetzki J
    Ann Intern Med; 1990 Dec; 113(12):921-5. PubMed ID: 2240917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide.
    Giustina A; Boni E; Romanelli G; Grassi V; Giustina G
    Am J Cardiol; 1995 May; 75(15):1042-7. PubMed ID: 7747686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly.
    Grunstein RR; Ho KK; Sullivan CE
    Ann Intern Med; 1994 Oct; 121(7):478-83. PubMed ID: 8067645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiac morphology and performance alterations and analysis of determinant factors of left ventricular hypertrophy in 40 patients with acromegaly].
    Casini AF; Araújo PB; Fontes R; Xavier SS; Gadelha MR
    Arq Bras Endocrinol Metabol; 2006 Feb; 50(1):82-90. PubMed ID: 16628279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML; Harris AG
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study.
    Hansen TB; Gram J; Bjerre P; Hagen C; Bollerslev J
    Clin Endocrinol (Oxf); 1994 Sep; 41(3):323-9. PubMed ID: 7955439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion.
    Barkan AL; Beitins IZ; Kelch RP
    J Clin Endocrinol Metab; 1988 Jul; 67(1):69-73. PubMed ID: 2897974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
    Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
    Ezzat S; Ren SG; Braunstein GD; Melmed S
    J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.
    De Marinis L; Bianchi A; Mazziotti G; Mettimano M; Milardi D; Fusco A; Cimino V; Maira G; Pontecorvi A; Giustina A
    Pituitary; 2008; 11(1):13-20. PubMed ID: 17987389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
    Ezzat S; Redelmeier DA; Gnehm M; Harris AG
    J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.